Literature DB >> 9797023

Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts.

R J Santen1, J Martel, M Hoagland, F Naftolin, L Roa, N Harada, L Hafer, R Zaino, R Pauley, S Santner.   

Abstract

Breast tumors from post-menopausal women contain higher amounts of estradiol than would be predicted from levels circulating in plasma. This observation raised the hypothesis that tumors may synthesize estradiol in situ and increase their tissue estradiol levels via this mechanism. The key enzyme involved in tissue estrogen synthesis, aromatase, is present in breast tumors but, according to some investigators, not in sufficient concentration to be biologically meaningful. We postulated that foci of cells in breast tumors might contain high amounts of aromatase and this locally produced estrogen might act in a paracrine or autocrine fashion. To test this hypothesis, we utilized immunohistochemistry to localize the aromatase enzyme, an histological scoring system to quantitate it, and culture of isolated breast cells to demonstrate its potential regulation. In 26 archival breast tumors, 16 (62%) contained aromatase by radiometric assay. With the immunohistochemical method, we detected areas with staining in the stroma as well as tumor epithelial cells. Staining ranged from the intensity approaching that seen in placenta to levels just distinguishable from background. We adopted an histological scoring system (H-score) from that used to quantitate progesterone receptor levels in tissue and used it to quantitate aromatase activity. A higher histologic score was found in stromal spindle cells (13) than in tumor epithelial cells (4.8). The biochemical aromatase results correlated with the H-score of stromal but not epithelial cells. To further study stromal cells from tumors, we isolated stromal cells from breast tumors and the benign areas of breast distal to the tumor and grew them in culture. Addition of dexamethasone, phorbol esters, and cyclic AMP analogues stimulated aromatase enzyme and messenger RNA levels substantially. Use of aromatase enzyme inhibitors such as letrozole blocked estrogen production but did not alter aromatase message levels. Epithelial cells, whether nonmalignant or cancer derived, exhibited no regulation by dexamethasone, phorbol esters, or cAMP analogues. These data, taken together, suggest that stromal cells may be more important than epithelial cancer cells for estrogen production in breast tumors. The ability to stimulate aromatase activity substantially with various enhancers of aromatase provides further credence for an important biologic role of estrogen production in tumor tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797023     DOI: 10.1023/a:1006081729828

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

Review 1.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.

Authors:  Srilatha Swami; Aruna V Krishnan; Jennifer Y Wang; Kristin Jensen; Lihong Peng; Megan A Albertelli; David Feldman
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

3.  Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase.

Authors:  Gui-Jian Liu; Giujian Liu; Yu-Sheen Wu; David Brenin; Wei Yue; Sarah Aiyar; Anne Gompel; Ji-Ping Wang; Rajeshwar Rao Tekmal; Richard J Santen
Journal:  Breast Cancer Res Treat       Date:  2007-11-02       Impact factor: 4.872

Review 4.  Breast cancer chemoprevention: beyond tamoxifen.

Authors:  C J Fabian
Journal:  Breast Cancer Res       Date:  2001-01-17       Impact factor: 6.466

5.  In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Authors:  Anne E Lykkesfeldt; Katrine L Henriksen; Birgitte B Rasmussen; Hironobu Sasano; Dean B Evans; Susanne Møller; Bent Ejlertsen; Henning T Mouridsen
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

Review 6.  The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.

Authors:  C J Fabian
Journal:  Int J Clin Pract       Date:  2007-09-24       Impact factor: 2.503

7.  Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.

Authors:  Zhenhuan Zhang; Hiroko Yamashita; Tatsuya Toyama; Yoko Omoto; Hiroshi Sugiura; Yasuo Hara; Xueqing Wu; Shunzo Kobayashi; Hirotaka Iwase
Journal:  Breast Cancer Res       Date:  2003-10-09       Impact factor: 6.466

Review 8.  The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy.

Authors:  Giorgio Dell'Acqua; Aleksander Richards; M Julie Thornton
Journal:  Nutrients       Date:  2020-11-18       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.